PT1107744E - Utilizacao de antagonistas da substancia p para o tratamento do sindrome de fadiga cronica e/ou fibromialgia - Google Patents
Utilizacao de antagonistas da substancia p para o tratamento do sindrome de fadiga cronica e/ou fibromialgiaInfo
- Publication number
- PT1107744E PT1107744E PT99942911T PT99942911T PT1107744E PT 1107744 E PT1107744 E PT 1107744E PT 99942911 T PT99942911 T PT 99942911T PT 99942911 T PT99942911 T PT 99942911T PT 1107744 E PT1107744 E PT 1107744E
- Authority
- PT
- Portugal
- Prior art keywords
- antagonists
- treatment
- substance
- fibromyalgia
- failure syndrome
- Prior art date
Links
- 208000001640 Fibromyalgia Diseases 0.000 title abstract 2
- 239000005557 antagonist Substances 0.000 title 1
- 230000001684 chronic effect Effects 0.000 title 1
- 239000000126 substance Substances 0.000 title 1
- 208000011580 syndromic disease Diseases 0.000 title 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 abstract 2
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 abstract 2
- 239000003890 substance P antagonist Substances 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- KPUPBSZZGVEESV-UHFFFAOYSA-N n-(1-benzoyl-2-benzylpiperidin-4-yl)isoquinoline-1-carboxamide Chemical class N=1C=CC2=CC=CC=C2C=1C(=O)NC(C1)CCN(C(=O)C=2C=CC=CC=2)C1CC1=CC=CC=C1 KPUPBSZZGVEESV-UHFFFAOYSA-N 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000000952 serotonin receptor agonist Substances 0.000 abstract 1
- 230000000697 serotonin reuptake Effects 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/452—Piperidinium derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Nutrition Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Communicable Diseases (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9818467.4A GB9818467D0 (en) | 1998-08-25 | 1998-08-25 | Organic compounds |
| GBGB9826692.7A GB9826692D0 (en) | 1998-12-04 | 1998-12-04 | Organic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT1107744E true PT1107744E (pt) | 2003-08-29 |
Family
ID=26314255
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT99942911T PT1107744E (pt) | 1998-08-25 | 1999-08-24 | Utilizacao de antagonistas da substancia p para o tratamento do sindrome de fadiga cronica e/ou fibromialgia |
Country Status (14)
| Country | Link |
|---|---|
| US (5) | US20030092735A1 (https=) |
| EP (1) | EP1107744B1 (https=) |
| JP (1) | JP4510290B2 (https=) |
| CN (1) | CN1216598C (https=) |
| AT (1) | ATE238044T1 (https=) |
| AU (1) | AU5624599A (https=) |
| BR (1) | BR9913201A (https=) |
| CA (1) | CA2339628C (https=) |
| DE (1) | DE69907220T2 (https=) |
| DK (1) | DK1107744T3 (https=) |
| ES (1) | ES2198948T3 (https=) |
| PT (1) | PT1107744E (https=) |
| TW (1) | TW200529847A (https=) |
| WO (1) | WO2000010545A2 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE265209T1 (de) | 1996-07-17 | 2004-05-15 | Merck & Co Inc | Änderung des zirkadischen rhythmus mit nicht- peptidischen neurokinin-1 rezeptor antagonisten |
| JP4510290B2 (ja) * | 1998-08-25 | 2010-07-21 | ノバルティス アーゲー | 慢性疲労症候群および／または線維筋痛の処置のためのサブスタンスｐアンタゴニストの使用および慢性疲労症候群の処置のためのｎｋ−１レセプターアンタゴニストの使用 |
| UA76810C2 (uk) | 2001-12-10 | 2006-09-15 | Мерк Енд Ко., Інк. | Фармацевтична композиція антагоніста рецептора тахікініну у формі наночастинок |
| GB0220953D0 (en) | 2002-09-10 | 2002-10-23 | Novartis Ag | Organic compounds |
| WO2004029944A1 (ja) * | 2002-09-30 | 2004-04-08 | Nec Corporation | 記録条件設定方法及びそれを用いた情報記録装置 |
| GB0402679D0 (en) * | 2004-02-06 | 2004-03-10 | Novartis Ag | Organic compounds |
| CN101190330A (zh) | 2006-11-30 | 2008-06-04 | 深圳市鼎兴生物医药技术开发有限公司 | 胆碱酯酶在拮抗速激肽药物中的应用 |
| CN101668527A (zh) * | 2007-02-23 | 2010-03-10 | 阿韦拉制药股份有限公司 | 药物制剂 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX18467A (es) * | 1988-11-23 | 1993-07-01 | Pfizer | Agentes terapeuticos de quinuclidinas |
| UA41251C2 (uk) * | 1990-01-04 | 2001-09-17 | Пфайзер, Інк. | Гідровані азотвмісні гетероциклічні сполуки, похідні піперидину, фармацевтична композиція та спосіб пригнічення активності речовини р в організмі |
| JPH072740B2 (ja) * | 1990-06-01 | 1995-01-18 | フアイザー・インコーポレイテツド | ３―アミノ―２―アリールキヌクリジン |
| MY110227A (en) * | 1991-08-12 | 1998-03-31 | Ciba Geigy Ag | 1-acylpiperindine compounds. |
| JPH05262654A (ja) * | 1992-03-18 | 1993-10-12 | Kaken Pharmaceut Co Ltd | 慢性疲労症候群治療剤 |
| TW397825B (en) * | 1994-10-14 | 2000-07-11 | Novartis Ag | Aroyl-piperidine derivatives |
| EP0802912B1 (en) * | 1995-01-12 | 2004-10-13 | Glaxo Group Limited | Piperidine derivatives having tachykinin antagonist activity |
| AU4918796A (en) | 1995-02-10 | 1996-08-27 | Eli Lilly And Company | Methods of treating or preventing psychiatric disorders |
| TW475930B (en) * | 1995-04-24 | 2002-02-11 | Novartis Ag | Novel compound, its use and pharmaceutical composition comprising it |
| TW531537B (en) | 1995-12-27 | 2003-05-11 | Janssen Pharmaceutica Nv | 1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives |
| WO1997033581A1 (en) | 1996-03-13 | 1997-09-18 | Yale University | Smoking cessation treatments using naltrexone and related compounds |
| WO1997038692A1 (en) | 1996-04-12 | 1997-10-23 | Eli Lilly And Company | Bisindoles for treating pain or nociception |
| US5891875A (en) * | 1996-05-20 | 1999-04-06 | Eli Lilly And Company | Morpholinyl tachykinin receptor antagonists |
| US5837252A (en) * | 1996-07-01 | 1998-11-17 | Larreacorp, Ltd. | Nontoxic extract of Larrea tridentata and method of making same |
| CA2273810A1 (en) | 1996-12-02 | 1998-06-11 | Merck Sharp & Dohme Limited | Use of nk-1 receptor antagonists for treating major depressive disorders |
| WO1999017609A1 (en) * | 1997-10-07 | 1999-04-15 | Larreacorp, Ltd. | Nontoxic extract of larrea tridentata and method of making the same |
| JP4510290B2 (ja) * | 1998-08-25 | 2010-07-21 | ノバルティス アーゲー | 慢性疲労症候群および／または線維筋痛の処置のためのサブスタンスｐアンタゴニストの使用および慢性疲労症候群の処置のためのｎｋ−１レセプターアンタゴニストの使用 |
-
1999
- 1999-08-24 JP JP2000565867A patent/JP4510290B2/ja not_active Expired - Fee Related
- 1999-08-24 WO PCT/EP1999/006215 patent/WO2000010545A2/en not_active Ceased
- 1999-08-24 CN CN99810017XA patent/CN1216598C/zh not_active Expired - Fee Related
- 1999-08-24 AU AU56245/99A patent/AU5624599A/en not_active Abandoned
- 1999-08-24 DE DE69907220T patent/DE69907220T2/de not_active Expired - Lifetime
- 1999-08-24 ES ES99942911T patent/ES2198948T3/es not_active Expired - Lifetime
- 1999-08-24 EP EP99942911A patent/EP1107744B1/en not_active Expired - Lifetime
- 1999-08-24 CA CA002339628A patent/CA2339628C/en not_active Expired - Fee Related
- 1999-08-24 DK DK99942911T patent/DK1107744T3/da active
- 1999-08-24 PT PT99942911T patent/PT1107744E/pt unknown
- 1999-08-24 AT AT99942911T patent/ATE238044T1/de active
- 1999-08-24 BR BR9913201-0A patent/BR9913201A/pt not_active Application Discontinuation
- 1999-08-31 TW TW094103860A patent/TW200529847A/zh unknown
-
2002
- 2002-08-16 US US10/222,060 patent/US20030092735A1/en not_active Abandoned
-
2004
- 2004-09-23 US US10/947,967 patent/US20050096334A1/en not_active Abandoned
-
2007
- 2007-03-08 US US11/715,805 patent/US20070155759A1/en not_active Abandoned
-
2008
- 2008-01-14 US US12/008,777 patent/US7713984B2/en not_active Expired - Fee Related
-
2009
- 2009-11-13 US US12/618,388 patent/US20100055176A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2339628A1 (en) | 2000-03-02 |
| US20050096334A1 (en) | 2005-05-05 |
| CA2339628C (en) | 2008-06-03 |
| US7713984B2 (en) | 2010-05-11 |
| ES2198948T3 (es) | 2004-02-01 |
| DE69907220T2 (de) | 2004-02-05 |
| AU5624599A (en) | 2000-03-14 |
| CN1348372A (zh) | 2002-05-08 |
| WO2000010545A2 (en) | 2000-03-02 |
| US20080161329A1 (en) | 2008-07-03 |
| US20100055176A1 (en) | 2010-03-04 |
| TW200529847A (en) | 2005-09-16 |
| DE69907220D1 (de) | 2003-05-28 |
| ATE238044T1 (de) | 2003-05-15 |
| BR9913201A (pt) | 2001-05-08 |
| EP1107744B1 (en) | 2003-04-23 |
| US20070155759A1 (en) | 2007-07-05 |
| JP2002523363A (ja) | 2002-07-30 |
| DK1107744T3 (da) | 2003-07-28 |
| EP1107744A2 (en) | 2001-06-20 |
| JP4510290B2 (ja) | 2010-07-21 |
| WO2000010545A3 (en) | 2000-08-10 |
| CN1216598C (zh) | 2005-08-31 |
| US20030092735A1 (en) | 2003-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0311436A (pt) | Derivados de 1-(aminoalquil)-3-sulfoni-lindol e -indazol como ligandos da 5-hidroxitriptamina-6 | |
| BRPI0418102A (pt) | derivados de quinolina | |
| AP2002002481A0 (en) | Biaryl ether derivatives useful as monoamine reuptake inhibitors. | |
| NO20050007L (no) | 1-Heterosyklylalkyl-3-sulfonylazaindol eller -azaindazolderivater som 5-hydroksytryptamin-6 ligander | |
| BR0116063A (pt) | Inibidores de sulfonamida heterocìclica da produção de beta amilóide e seus usos | |
| EA200300528A1 (ru) | 1-арил-или 1-алкилсульфонилгетероциклилбензазолы в качестве лигандов 5-гидрокситриптамина-6 | |
| BR0109703A (pt) | Derivados de piperazina | |
| NO20050014L (no) | 1-Heterosyklylalkyl-3-sulfonylindol eller -indazolderivater som 5-hydroksytryptamin-6 ligander | |
| NO20061737L (no) | Aminosubstituerte erylamino B2 adrenergiske receptoragonister | |
| NO20044763L (no) | 1-(aminoalkyl)-3-sulfonylazaindoler som 5-hydroksytryptamin-6 ligander | |
| ITRM20010356A1 (it) | "5-alogeno derivati della triptamina utili come ligandi del recettore5-ht6 e/o 5-ht7 della serotonina. | |
| NO20063620L (no) | Arylanilinderivater som beta2 adrenergiske receptoragonister | |
| AR029454A1 (es) | Derivados de piperazina sustituidos, procedimientos para su preparacion, composiciones farmaceuticas que los contienen y su uso en la elaboracion de medicamentos | |
| BR9811482A (pt) | Derivados de 1-(n-fenilaminoalquil)-piperazina substituìda na posição 2 do anel fenìlico | |
| PT1107744E (pt) | Utilizacao de antagonistas da substancia p para o tratamento do sindrome de fadiga cronica e/ou fibromialgia | |
| BR0213393A (pt) | Derivados de éter alquìlico e de alquilamida ou seus sais, processos para produzir um derivado de éter alquìlico, e, composição farmacêutica | |
| BRPI0713132B8 (pt) | compostos derivados de cinamoil-piperazina, método de preparação dos referidos compostos, composições farmacêuticas, seus usos como antagonistas de par-i e produtos | |
| BR0007718A (pt) | Utilização de derivados depiridazino[4,5-b]indol-1-acetamida para preparaçãode medicamentos para doenças ligadas à disfunçãode receptores de benzodiazepina do tipoperiférico | |
| BR0306147A (pt) | Uso de um composto ou combinação de compostos tendo atividade agonìstica de receptor de dopamina-d2 parcial e atividade inibidora de reabsorção da serotonina e/ou noradrenalina, método para a preparação de uma composição, e, composição | |
| EA200301143A1 (ru) | Производные гетероциклилалкокси-, алкилтио- и -алкиламинобензазола в качестве лигандов 5-гидрокситриптамина-6 | |
| BRPI0411095B8 (pt) | derivados de imidazol, seus usos e seus processos de preparação, e medicamentos | |
| BRPI0417946A (pt) | composto, métodos para o tratamento ou a profilaxia de uma doença ou condição, e de distúrbios, e para a indução da cessação do hábito de fumar, composição farmacêutica, e, uso de um composto | |
| BR0207438A (pt) | Novos derivados de 5-ciano-1h-indol antagonista dos receptores da interleucina-8 | |
| BR0013723A (pt) | Uso de bissulfonamidas, para produção de medicamentos para profilaxia ou tratamento de hiperlipidemia | |
| DK1301475T3 (da) | Arylsulfonamider, som serotoninantagonist til behandling af obesitet |